Strategic Focus IgGenix is a clinical-stage, venture-backed biotechnology company focused on allergic disease, notably Alpha-gal Syndrome and IgG4 antibody therapeutics, presenting opportunities for collaboration or strategic partnerships in specialty immunology and translational research.

Clinical Pipeline Their lead activities include monoclonal IgG4 antibody discovery and peanut allergy therapeutics, suggesting potential for ongoing collaborations with pharma companies or contract research organizations seeking access to novel antibody platforms or preclinical services.

Investments & Growth With a $75M funding base and recent Series B activity, IgGenix is positioned for expansion in preclinical development and partner-driven programs, offering co-development or investment-friendly opportunities for specialist biotech investors and strategic alliances.

Market Positioning Operating from South San Francisco and actively presenting at major allergy congresses, IgGenix demonstrates industry engagement and visibility, signaling readiness for out-licensing, collaboration on biomarker validation, and access to a network of allergy-focused clinicians and researchers.

Technology & Ops Leveraging a tech stack centered on modern cloud and web infrastructure (Google Cloud, WordPress, Google Workspace) indicates scalable data management and outreach capabilities, enabling potential service collaborations in data management, analytics, or digital engagement for clinical research programs.